A carregar...
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810481/ https://ncbi.nlm.nih.gov/pubmed/33463535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI143226 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|